Malignant Exocrine Pancreas Neoplasm

subtype

Identifier: CI-CAN-00003152
Entity page: /cancer/malignant-exocrine-pancreas-neoplasm ↗
Edges: 1,211

Neighbours: 16 genes1 variants16 drugs10 trials
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Exocrine Pancreas Neoplasm approved for …APPROVED_FORderived8 of 8
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Pancreatic Adenocarcinoma	—	approved	Pancreatic Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for	Paclitaxelsmall molecule FDA (US) · approved · 2023-05-11 · Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Loss-of-function OlaparibFDA US 2017-08-176 active / 10 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-176 active / 10 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA2 in this cancerRegulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 0 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma
SLC29A1 Overexpression Gemcitabine58 active / 175 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for SLC29A1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma
KRAS Wildtype Afatinib1 active / 2 trials
Curatedlevel Csensitivity· support 2civicObservedKRAS altered in 41% (168 / 412 cases, largest of 10 cohorts)no approval record in this cancercontext: Pancreatic Ductal Adenocarcinoma
ALK Fusion Alectinib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Pancreatic Acinar Cell Carcinoma
EGFR L747_P753delinsS Erlotinib1 active / 6 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for EGFR in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma
NRG1 Fusion Afatinib1 active / 2 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Ductal Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Exocrine Pancreas Neoplasm prognostic in …PROGNOSTIC_IN1 of 1
← prognostic in	KRAS G12DSNV	supports	B	Malignant Exocrine Pancreas Neoplasm	1	Curated	civic	graph →

Malignant Exocrine Pancreas Neoplasm associated with …ASSOCIATED_WITH1 of 1
← associated with	KRAS	supports	B	Malignant Exocrine Pancreas Neoplasm	1	Curated	civic	graph →

Malignant Exocrine Pancreas Neoplasm altered in cohorts of …ALTERED_INderived15 of 109show all (up to 200)
← altered in cohorts of	CFAP53 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CXXC1 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MAPK4 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MBD1 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ME2 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SKA1 114 / 185 cases (62 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	C18orf54 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DCC 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MBD2 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MEX3C 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRO 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYO5B 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POLI 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	STARD6 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TCF4 113 / 185 cases (61 %) · ssm · TCGA-PAAD	—	—	Pancreatic Adenocarcinoma	1	Observed	gdc	graph →

Malignant Exocrine Pancreas Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 162show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 175 trials (58 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	175	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 102 trials (45 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 68 trials (29 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	68	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 54 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 51 trials (25 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 51 trials (25 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 34 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 21 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 20 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 17 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 16 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 14 trials (9 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 12 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Exocrine Pancreas Neoplasm	10	Observed	clinicaltrials	graph →

Malignant Exocrine Pancreas Neoplasm studied in …STUDIED_INderived10 of 930show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 930 trials mapped (417 active)	—	—	Exocrine Pancreas Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ONTOLOGY_EXACT · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06608927Phase 3 · active not recruiting Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma · condition mapped CURATED_BROADER · 930 trials mapped (417 active)	—	—	Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07845617recruiting Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma · condition mapped ALIAS · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · condition mapped ONTOLOGY_EXACT · 930 trials mapped (417 active)	—	—	Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06388967recruiting Pancreatic Cancer Detection Consortium · condition mapped ONTOLOGY_EXACT · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · condition mapped ALIAS · 930 trials mapped (417 active)	—	—	Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 930 trials mapped (417 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →